Evaluation of the therapeutic efficacy of praziquantel against schistosomes

In seven countries with ongoing large-scale deworming programs

From:
Foreign, Commonwealth & Development Office
Published
17 October 2020
Country:
Brazil, Cameroon, Ethiopia, Madagascar, Mali, Niger, Nigeria, Philippines, Senegal, Tanzania
Document Type:
Journal Article
Theme:
Agriculture
Authors:
Levecke, B, Vlaminck, J, Andriamaro, L, Ame, S

Abstract

The World Health Organization (WHO) recommends periodic assessment of the therapeutic efficacy of praziquantel (PZQ) to detect reduced efficacy that may arise from drug resistance in schistosomes. In this multi-country study (2014), we assessed the therapeutic efficacy of a single oral dose of PZQ (40 mg/kg) against Schistosoma mansoni (Brazil, Cameroon, Ethiopia, Mali, Madagascar and Tanzania), S. haematobium (Cameroon, Ethiopia, Mali, Tanzania and Zanzibar) and S. japonicum (the Philippines) infections in school-aged children, across a total of 12 different trials.

This is a publication arising from the Zoonoses and Emerging Livestock Systems (ZELS) programme.

Citation

Levecke B, Vlaminck J, Andriamaro L, Ame S, Belizario V, Degarege A, Engels D, Erko B, Garba A, Kaatano G, Mekonnen Z, Montresor A, Olliaro P, Pieri O, Sacko M, Sam-Wobo S, Tchuem Tchuenté L, Webster J, Vercruysse J (2020). Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs. Int J Parasitol Drugs Drug Resist. 14:183-187.

Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs

Updates to this page

Published 17 October 2020
Contents